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Abstract 
 
Background and aim  Assessment of volume of distribution (VD) and half-life (T½) values during 
glomerular filtration rate (GFR) investigations is a useful quality control check. The aim of this 
study was to derive reference data for VD and T½ and also to provide reference data for GFR 
from studies performed using 
99m
Tc-diethylenetriaminepentaacetic acid (
99m
Tc-DTPA).  
 
Methods  This was a retrospective study of 126 healthy potential kidney donors (age range 18-
59 years). GFR was evaluated from 
99m
Tc-DTPA plasma clearance using the 2004 British 
Nuclear Medicine Society guidelines. The association between VD and body surface area (BSA) 
was assessed. T½ was correlated with age and with GFR. The correlation between Brochner-
Mortensen-corrected GFR (BM-GFRCorr) and age was evaluated.  
 
Results  Uncorrected VD (L) was (10.1*BSA) ± 40.6% (p<0.01).  Corrected VD (L) was 
(8.19*BSA) ± 34.4% (p<0.01). In individuals under the age of 40 years mean T½ was 95.0 min ± 
36.2%. In individuals 40 years and older, T½ increased at a rate of 0.49 min/year (p=0.04). T½ 
(min) was [9480*(1/BM-GFRCorr)] ± 35.1% (p<0.01). In individuals younger than 40 years the 
correlation of BM-GFRCorr and age was not statistically significant (p=0.45) and mean GFR was 
108 ml.min
-1
.(1.73m
2
)
-1
 ± 27.5%. In individuals 40 years and older BM-GFRCorr was [170 - 
(1.55*age)] [ml.min
-1
.(1.73m
2
)
-1
] ± 36.7% (p<0.001).  
 
Conclusion  Well defined reference data for VD and T½ can be used as quality control checks in 
GFR investigations. In addition to these, reference data for GFR using 
99m
Tc-DTPA have been 
defined. This will enhance the interpretation of adult 
99m
Tc-DTPA GFR measurements.  
Keywords: 
99m
Tc-DTPA, volume of distribution, half-life, glomerular filtration rate, reference 
ranges 
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Introduction 
 
Glomerular filtration rate (GFR) is a standard measure of renal function. Although measuring 
plasma inulin clearance remains the gold standard for determining GFR, this technique is rarely 
used because it is time-consuming and difficult to perform [1,2]. An estimate of GFR can be 
obtained by measuring creatinine clearance; however, this technique is inaccurate, especially in 
cases of poor renal function [3,4]. Measurement of GFR using Nuclear Medicine techniques is 
considered a suitable alternative with clearance of 
51
Cr-ethylenediaminetetraacetic acid
 
(
51
Cr-
EDTA) having been shown to be similar to that of inulin [5,6]. 
 
99m
Tc-diethylenetriaminepentaacetic acid (
99m
Tc-DTPA) is considered an acceptable alternative 
to 
51
Cr-EDTA [1,2]. It has the advantages of being inexpensive, widely available and the 
radiation dose to the patient is low. It is also suitable for gamma camera imaging, allowing 
simultaneous acquisition of a renogram for calculation of differential renal function. Clearance of 
99m
Tc-DTPA has been shown to correlate well with 
51
Cr-EDTA clearance [7].  
 
In 2004 the British Nuclear Medicine Society (BNMS) published guidelines for the measurement 
of GFR [2]. The authors recommended measuring the plasma clearance of either 
51
Cr-EDTA or 
99m
Tc-DTPA using the slope-intercept method with Brochner-Mortensen correction [2,8]. In the 
clinical context this method provides a good compromise between accuracy and simplicity. 
Nevertheless, careful attention to technique is warranted since methodological errors can be 
introduced at a number of stages [9]. These include, amongst others, errors in height or weight 
measurement, drawing up and injection of the patient dose, preparation or measurement of the 
standard, and preparation or measurement of the plasma samples. 
 
The slope-intercept method does, however, offer a number of opportunities for quality control of 
the procedure [2]. Two parameters obtained during the calculation of GFR using the slope-
intercept method are the volume of distribution (VD) and the half-life (T½) of the injected 
radiopharmaceutical [8]. While being of limited value for predicting the GFR in isolation, these 
values can be valuable to check for underlying methodological errors [2,10,11]. Using VD and T½ 
for this purpose requires clearly defined reference ranges for each of these parameters. The 
BNMS guidelines provide a reference range for the uncorrected VD (L) as being linearly related 
to body surface area (BSA) (m
2
) by the equation [2]: 
 
VD (uncorrected) = (8*BSA) ± 25% (2SD)           (1)    
 
This range for VD was obtained using 
51
Cr-EDTA. It applies to an uncorrected value for VD, 
calculated using the formula: 
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VD (uncorrected) = A/C             (2)   
  
where A is the administered activity and C the intercept at zero time obtained by back 
extrapolation of the terminal exponential of the curve of activity per unit volume versus time [12, 
Personal communication: G. Blake, King’s College London, UK].  
 
The Medical Physics Department of University Hospital Southampton NHS Foundation Trust, 
UK, found the corrected VD for 
99m
Tc-DTPA to be related to BSA by the equation [13]: 
 
VD (corrected) = (6.61*BSA
1.218
)
 
± 32% (2SD)          (3) 
 
The values for VD were calculated using the equation: 
 
VD (corrected) = BM-GFR / k             (4)  
 
where BM-GFR is the Brochner-Mortensen-corrected GFR [8] and k is the slope of the terminal 
exponential.  
 
Equation 2 leads to an overestimation of the volume of distribution as it takes into account only 
the terminal exponential of the plasma clearance curve after mixing has taken place between 
the vascular and extravascular compartments [12]. The degree of overestimation is similar to 
that found when calculating GFR by the slope-intercept method without Brochner-Mortensen 
correction. The corrected volume of distribution, VD (corrected) (equation 4), although still an 
approximation since it assumes k is the terminal exponential, tries to correct for the 
overestimation.   
 
A technique of measuring extracellular fluid volume (ECV) using a combination of the slope-only 
and slope intercept methods has been described and validated [14,15]. Using this technique, 
reference data for ECV have recently been described by Peters et al in a large multi-centre 
study in the UK [16]. 
 
In the BNMS guidelines T½ is described as being “typically in the range” of 100-120 min in 
adults [2]. However, to the authors’ knowledge no data has been published supporting the use 
of the above or other reference ranges for VD and T½. Specifically, there is a lack of published 
data for normal values of VD and T½ that have been determined using 
99m
Tc-DTPA [17].  
 
Reference data for GFR have been well-defined by Granerus [18], Hamilton et al [19], Grewal 
and Blake [20], as well as by Peters et al [16]. Although previous studies have shown only a 
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small difference in GFR values obtained using 
51
Cr-EDTA and 
99m
Tc-DTPA [21,22], there are no 
published reference ranges for GFR using 
99m
Tc-DTPA.   
 
The aim of this study was to determine reference values for VD and T½ from GFR studies using 
99m
Tc-DTPA in a healthy population. In addition, reference data for GFR using 
99m
Tc-DTPA have 
been defined for the study population.  
 
Methods 
 
Patient population: 
This retrospective study included the GFR studies of all potential kidney donors referred to the 
Nuclear Medicine Department of Tygerberg Hospital, Cape Town, South Africa, between 
February 2007 and September 2012. In total 128 GFR studies were performed and 126 of these 
were included in the study (69 females, 57 males; age range 18-59 years). Two studies were 
excluded; one due to discrepancies with weight measurements and one as it was performed 
using 
51
Cr-EDTA. In 113 subjects a renogram was performed in combination with the GFR 
study, while in 13 subjects the GFR study was performed on a different day to the renogram. All 
potential donors underwent a screening process by the hospital’s Renal Unit. Subjects were 
excluded if they had chronic diseases that could potentially affect renal function or that placed 
them in a high-risk surgical category. Hypertension, diabetes mellitus and psychiatric illness 
were considered absolute contraindications to kidney donation. The initial blood tests included 
haematological and biochemical parameters (urea, creatinine, full blood count, liver function, 
sodium, potassium, chloride, calcium, magnesium, inorganic phosphate, uric acid, glucose), as 
well as serology for HIV, syphilis, hepatitis A, hepatitis B, hepatitis C, and cytomegalovirus. If 
these tests were normal and the subject was considered a match based on ABO compatibility 
and T-cell cross-matching, more specific renal screening was performed. GFR was estimated 
from a plasma creatinine sample using either the Modification of Diet in Renal Disease (MDRD) 
[23] or Cockgroft-Gault formula [24]. In addition, creatinine clearance was calculated from a 24-
hour urine collection, 24-hour urinary protein excretion was determined, and a spot urine 
sample was collected to determine the protein-to-creatinine ratio. Only if the results of all tests 
were normal were subjects referred to the Nuclear Medicine department for a renogram and 
GFR study. 
 
This work was approved by the Stellenbosch University Health Research Ethics Committee; 
study number N10/05/177.  
 
Measurement of GFR, VD and T½: 
All GFR studies were performed based on the protocol described in the BNMS guidelines [2]. 
The subjects’ heights and weights were recorded and the BSA calculated using the Haycock 
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formula [25]. 
99m
Tc-DTPA (TechneScan® DTPA, Covidien) was injected intravenously. Labelling 
efficiency was greater than 90% in all cases. The injection site was imaged to exclude 
extravasation. The dose was approximately 40 MBq when only the GFR study was performed 
on that visit, and about 400 MBq when the GFR study was combined with a renogram. The 
patient and standard doses were accurately calibrated by weighing the syringes pre- and post-
injection on a Precisa 620 C balance, without flushing the syringes or removing the needles. 
Three 8 ml venous blood samples were drawn from the contralateral arm at 2, 3 and 4 hours 
respectively. The exact time of injection and the time of drawing each sample were recorded to 
the nearest minute. Samples were centrifuged immediately after being drawn. A standard was 
prepared by withdrawing a similar dose of 
99m
Tc-DTPA from the same kit and adding it to a half-
filled 100 ml flask, which was subsequently filled to the 100 ml mark with distilled water and 
mixed. Two millilitres of this solution was pipetted into a second 100 ml flask that was filled and 
mixed in a similar manner. The dilution volume of the standard was thus equivalent to 5 litres. 
Duplicate 1 ml aliquots of plasma samples and standard were pipetted into counting tubes. 
Background counts were recorded, followed by the counting of each sample in a Picker NaI(Tl) 
well counter. All samples were counted sequentially in one sitting. Linearity of the well counter 
was checked routinely and was acceptable, specifically at high count rates.      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
The GFR was calculated using the slope-intercept method as described in the 2004 BNMS 
guidelines
 
[2]. The natural logarithm of the plasma 
99m
Tc-DTPA concentrations were plotted 
against time. Linear regression analysis was used to determine the half-life (T½) and VD 
(uncorrected). The slope-intercept GFR (SI-GFR) was calculated using the equation [2]: 
 
SI-GFR = VD (Uncorrected) x (0.693/T½)            (5) 
 
The SI-GFR was then corrected for body surface area: 
 
SI-GFRCorr = SI-GFR x (1.73/BSA m
2
)           (6) 
 
Subsequently, the mean Brochner-Mortensen (BM) equation was applied to correct for the 
missing area under the curve from the fast exponential [2]: 
 
BM-GFRCorr = 1.0004 x SI-GFRCorr – 0.00146 x SI-GFR
2
Corr
 
        (7) 
 
The coefficients used in this equation are an average of those in the adult [8] and paediatric 
equations [26]. 
 
The absolute GFR was calculated by reversing the BSA correction: 
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BM-GFR = BM-GFRCorr x (BSA m
2
/1.73)           (8) 
 
For each GFR study the uncorrected VD was calculated using equation 2 and the corrected VD 
was calculated using equation 4. 
 
Using the methodology previously described [14-16], ECV-BSA (extracellular volume corrected 
to a BSA of 1.73 m
2
) was calculated for each individual. Correction for BSA was reversed by 
multiplication of ECV-BSA with BSA/1.73m
2
 to give ECV [16]. 
 
Defining reference ranges:  
Values for VD, both uncorrected and corrected, were plotted against BSA. Using linear 
regression analysis the correlation was determined between VD and BSA. Variability was 
defined by calculating the standard error of the estimate of the regression analysis.  This gives 
the standard deviation of estimating VD from BSA. In this report the 95% confidence limits, or 
two standard deviations, are expressed as a percentage relative to the mean VD value. These 
results were compared to the accepted reference ranges described earlier (equations 1 and 3) 
[2,13] and to the ECV-BSA data described by Peters et al [16]. 
 
In order to define reference data for T½, the correlations of T½ and age as well as T½ and 1/BM-
GFRCorr were determined. Similarly, the association between BM-GFRCorr and age was 
investigated using linear regression. Variability for these parameters was also described by the 
relative two standard deviation, expressed as a percentage. The results of the BM-GFRCorr vs. 
age correlation were compared to 
51
Cr-EDTA reference ranges described by Granerus [18], 
Hamilton [19] and Grewal and Blake [20] and to the mean values for GFR described by Peters 
et al [16].  
 
Deviations from BNMS guidelines 
The protocol used in this study deviated from the BNMS guidelines in two aspects and steps 
were taken to assess their impact on the calculated GFR and VD. Firstly, in 70 of the 126 
studies, low counts were recorded for some of the samples. The BNMS guidelines state that, 
where practical, a minimum of 10 000 counts should be obtained from each sample in order to 
reduce statistical error [2]. The effect of this factor on the accuracy of the GFR and VD was 
assessed by introducing simulated random error into the counts that were obtained from all 
samples in all 126 studies. This was repeated 10 times and GFR and VD were calculated in 
each instance. From this data, systematic, random and total error was estimated.  
 
A second deviation from the BNMS guidelines was that no correction was performed for decay 
of 
99m
Tc during the counting process. In order to quantify the error introduced by not correcting 
for radioactivity decay, an independent set of 26 GFR studies was evaluated. Counts obtained 
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from all samples in these studies were higher than 10 000 and the exact time at which each 
sample was counted was recorded. GFR and VD were then calculated for each study, with and 
without decay correction. From this set of data the systematic, random and combined errors 
were computed. 
 
Results 
The scatter graphs of the uncorrected VD (L) and corrected VD (L) as a function of the BSA (m
2
) 
are shown in figures 1 and 2 respectively with trendlines representing ± 2SD.  
 
The correlation between VD (L), both uncorrected and corrected, and BSA (m
2
) was significant 
(p < 0.001 for both correlations). Both were best described using linear functions: 
 
VD (Uncorrected) = (10.1 * BSA) L ± 40.6% (2SD)         (9) 
 
(RMSE = 3.70 L; 95% CI for the coefficient: 9.79 to 10.5 L).  
 
VD (Corrected) = (8.19 * BSA) L ± 34.4% (2SD)         (10) 
 
(RMSE = 2.53 L; 95% CI for the coefficient: 7.95 to 8.44 L).  
 
In figure 1 the trendlines representing the upper and lower limits of the range described in the 
BNMS guidelines (equation 1) [2] are displayed. Similarly, the trendlines representing the upper 
and lower limits of the range described by University Hospital Southampton NHS Foundation 
Trust, UK [13] are displayed in figure 2. 
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Fig. 1 
 
Scatter graph of the uncorrected values of volume of distribution [VD (uncorrected)] in litres plotted as a function of BSA. The 
central line represents equation 9, the upper and lower lines (dashes) represent ± 2SD (± 40.6%). The faint dotted lines 
represent the upper and lower limits of the reference range described in BNMS guidelines (8*BSA ± 25%) (2SD) [2]. 
There is overlap of the two lines representing - 2SD.  
 
Fig. 2 
 
Scatter graph of corrected values of volume of distribution [VD (corrected)] in litres plotted as a function of BSA. The central 
line represents equation 10, the upper and lower lines (dashes) are ± 2SD (± 34.4%). The faint dotted lines represent 
the upper and lower limits of the reference range determined by University Hospital Southampton (6.61*BSA
1.218
) ± 32% 
(2SD) [13]. 
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Mean ECV normalised for BSA (ECV-BSA) was 12.7 ± 4.4 (2SD) L/1.73 m
2
. ECV-BSA in men 
was 13.5 ± 4.9 (2SD) L/1.73 m
2
 and in women 12.0 ± 3.5 (2SD) L/1.73 m
2
. 
 
The association between T½ (min) and age (years) was not statistically significant (p = 0.16), nor 
was the association between T½ (min) and age (years) in subjects under the age of 40 years (p 
= 0.65). In this subgroup (< 40 years) the mean T½ was 95.0 ± 36.2% (2SD). In subjects 40 
years and older the association between T½ and age was statistically significant (p = 0.046). 
This bi-linear fit is illustrated in figure 3. Using linear regression the following equation describes 
the association in subjects 40 years and older: 
 
 T½ = [(0.49*age) + 75.9] min ± 30% (2SD)         (11)
   
     
The association between T½ (min) and 1/BM-GFRCorr (min.(1.73m
2
).ml
-1
) was statistically 
significant (p < 0.001) and it is illustrated in the scatter graph in figure 4. Using linear regression 
it was best described using the equation: 
 
T½ = 9480*(1/BM-GFRCorr) min ± 35.1% (2SD)        (12) 
 
Fig. 3 
 
Scatter graph of T½ (min) plotted as a function of age (years). The central line represents the mean in individuals under 
the age of 40 years and the equation-predicted-mean in individuals 40 years and older (equation 11). The upper and 
lower lines are ± 2SD (± 36.2% in individuals < 40 years and ± 36.7% in individuals ≥ 40 years 
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Fig. 4 
 
Scatter graph of T½ (min) plotted as a function of (1/BM-GFRCorr) [min.(1.73m
2
).ml
-1
)]. The central line represents T½ 
fitted to equation 12 and the upper and lower lines represent ± 2SD (± 35.1%). 
                       
Figure 5 is the scatter graph of BM-GFRCorr [ml.min
-1
.(1.73m
2
)
-1
] plotted as a function of age 
(years). In individuals younger than 40 years the correlation was not statistically significant (p = 
0.45). The mean GFR in this group was 108 ml.min
-1
.(1.73m
2
)
-1
 ± 27.5% (2SD). In individuals 40 
years and older the correlation between GFR and age was statistically significant (p < 0.001). 
The following equation describes this association: 
 
BM-GFRCorr = 170 – (1.55*age) [ml.min
-1
.(1.73m
2
)
-1
] ± 36.7% (2SD)              (13) 
 
Mean BM-GFRCorr in men was 107 ± 29.8 (2SD) [ml.min
-1
.(1.73m
2
)
-1
] and in women 100.7 ± 
35.8 (2SD) [ml.min
-1
.(1.73m
2
)
-1
]. This difference was statistically significant (p = 0.04), however, 
men were significantly younger than women, mean age 30.5 vs. 36.4 years (p = 0.003). 
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Fig 5 
 
Scatter graph of BM-GFRCorr [ml.min
-1
.(1.73m
2
)
-
1] as a function of age (18-59 years) in 126 potential kidney donors. 
GFR values were corrected for BSA and using the mean Brochner-Mortensen equation [2,8]. The central line represents 
the mean GFR in individuals under the age of 40 years and the mean fitted to equation 13 in individuals 40 years and 
older. The upper and lower lines represent ± 2SD (± 27.5% in individuals under the age of 40 years and 36.7% in 
individuals older than 40). 
 
Considering all 126 studies, the systematic and random errors (1SD) introduced to GFR data 
through statistical noise were -0.19% and 2.97% respectively, and for VD, 0.64% and 10.19% 
respectively. In the prospective series of 26 studies the systematic and random errors (1SD) 
introduced to GFR data through not correcting for radioactivity decay were -0.12% and 1.81% 
respectively, and for VD, -0.22% and 2.37% respectively. In this series the counting of all 
samples was completed within 14 minutes (range 6 – 14 min, mean 9 min). 
 
 
Discussion 
In this study reference ranges for a South African adult population were determined for VD, T½ 
and GFR using 
99m
Tc-DTPA and the slope-intercept method as described in the BNMS 
Guidelines [2]. The slope-intercept method remains prone to methodological errors [5,6] and 
various quality control checks have been proposed: the fit of the counts to a single exponential 
can be assessed, either graphically or by checking that the correlation coefficient is greater than 
0.985 [2]. Alternatively, slope-intercept GFR measurements can be checked using single-
sample estimates [27,28] or using the slope-only technique [9,14]. 
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VD and T½ are two quantities that are obtained during calculation of GFR using the slope-
intercept method. The BNMS guidelines recommend reviewing these quantities as an additional 
quality control check [2]. For this purpose it is necessary to compare values to normal values for 
VD and T½ defined for the patient population and for the radiopharmaceutical used. 
 
In the present study a reference range for uncorrected VD in litres was identified as (10.1 * BSA) 
± 40.6% (2SD). These values are systematically higher and show greater variability than those 
described in the BNMS guidelines (equation 1, fig. 1) [2]. Although the values for VD in the 
BNMS guidelines were derived from GFR measurements using 
51
Cr-EDTA, previous studies 
demonstrated no significant difference in VD between 
51
Cr-EDTA and 
99m
Tc-DTPA [21, 29]. 
Therefore, it is believed that it is unlikely that the radiopharmaceutical justifies for the 
differences between the BNMS range and the values in the current study.  
 
In this study the reference range for corrected VD in litres was found to be (8.19 * BSA) ± 34.4% 
(2SD). The variability for corrected VD (34.4%) is noted to be lower than for uncorrected VD 
(40.6%). This is expected because uncorrected VD is overestimated relative to the true value 
and the degree of overestimation depends on GFR. Thus a subject of a given size will have a 
higher value for uncorrected VD if GFR is normal than if it is reduced. This GFR-related 
variability of VD is reduced by applying a Brochner-Mortensen correction. 
 
In this study the values for corrected VD are systematically higher than those reported by 
University Hospital Southampton NHS Foundation Trust (equation 3, fig. 2) [13]. For example, 
for a BSA of 1.73 m
2
, the corrected VD using the Southampton equation would be 12.9 L whilst it 
would be 14.2 L using equation 11, leading to a 9% higher value. However, considering that the 
2SD error for the Southampton data is 32% and for the data in the current study it is 34.4%, the 
difference in variability between the two centres is within the estimated error on the VD. 
 
Radiopharmaceutical factors are even less likely to account for the differences in corrected VD 
between this centre and Southampton University Hospitals NHS Trust. In fact, both centres 
used TechneScan® DTPA, Covidien. This specifically excludes differences in protein binding of 
different DTPA preparations as a cause for the higher values or greater variability seen in VD.  
 
The study populations in the two centres differ. The Southampton data was obtained from a 
general clinical GFR population, which included normal and abnormal GFRs and both children 
and adults, while the data in this study was obtained from a carefully selected normal adult 
population. This will affect the uncorrected values of VD. The overestimation of uncorrected VD 
will be higher in the normal group compared to the mixed population as the GFR will on average 
be higher. In terms of environmental and ethnic factors, the population in this study is likely to 
be more diverse than a population originating from Southampton. The current study population 
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is heterogeneous, with roughly equal numbers of subjects of Caucasian, African and mixed 
ancestry. It has been shown in previous studies that there are differences in muscle mass 
amongst different ethnic groups and this may translate to differences in VD [30-32]. 
 
An additional factor contributing to the variability in the results for VD might have been 
experimental error due to low counts; however, this is thought to play a minor role and it will be 
discussed later in this section. 
 
Using the technique described by Peters et al ECV-BSA was calculated for each subject [14-
16]. The mean ECV-BSA was 12.7 ± 4.4 (2SD) L/1.73 m
2
, whilst for males it was 13.5 ± 4.9 
(2SD) L/1.73 m
2
 and females 12.0 ± 3.5 (2SD) L/1.73 m
2
. These GFR values were corrected for 
the one-pool assumption using the mean Brochner-Mortensen correction as recommended in 
the BNMS guidelines [2]. When corrected using the adult Brochner-Mortensen equation [8], 
ECV/BSA in males was 13.9 ± 5.1 (2SD) L/1.73 m
2
 and in females 12.3 ± 3.7 (2SD) L/1.73 m
2
. 
These values for ECV-BSA agree reasonably well with those described by Peters et al in their 
recent multi-centre UK-based study [16]. 
 
The mean value for ECV in this study is 27% lower than the mean value for uncorrected VD. 
This is in close agreement with previous work in which a difference of 30% was described [33]. 
The mean value for ECV-BSA in the current study is, however, also approximately 10% lower 
than the mean value for corrected VD normalized for BSA. This is due to the approximation used 
in this study that the slope of the second exponential is equal to the clearance constant.  The 
work of Bird et al [15] shows that the slope systematically underestimates the constant by about 
10% leading to an overestimate in the volume of distribution.  
 
Calculation of T½ may be used as a quality control check by comparing it against the value 
expected for the subject’s GFR. The association between T½ (min) and 1/BM-GFRCorr 
[min.(1.73m
2
).ml
-1
] was statistically significant (p < 0.001) and T½ (min) was found to be 
[9480*(1/BM-GFRCorr)] ± 35.1%. 
 
In the study by Grewal and Blake, the authors noted that it was apparent that there was a break 
in the age dependence of GFR at approximately 40 years [20]. They found no statistically 
significant correlation between GFR and age for individuals under the age of 40 years, while 
there was a statistically significant decrease in GFR from the age of 40 years onward. In this 
study a cut-off of 40-years was used based on this work and it supports that conclusion: for 
individuals under the age of 40, the correlation between GFR and age was not statistically 
significant (p = 0.45), while it was significant (p < 0.001) in individuals 40 years and older. In 
individuals younger than 40 years the mean BM-GFRCorr was 108 ml.min
-1
.(1.73m
2
)
-1
. This is the 
same as the 108 ml.min
-1
.(1.73m
2
)
-1
 reported by Hamilton et al [19], but higher than the 103 
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ml.min
-1
.(1.73m
2
)
-1 
reported by Grewal and Blake [20] and the 105 ml.min
-1
.(1.73m
2
)
-1
 reported 
by Granerus and Aurell [18]. The slightly higher GFR is expected for DTPA compared to EDTA 
[21-22]. In individuals 40 years and older, BM-GFRCorr was expressed by the linear relation 170 
– (1.55*age) [ml.min
-1
.(1.73m
2
)
-1
]
 
± 36.7% (2SD). In this study the reference curve predicts a 
mean GFR at age 50 years of 93 ml.min
-1
.(1.73m
2
)
-1
. This is in good agreement with the mean 
of 94 ml.min
-1
.(1.73m
2
)
-1
 found by Grewal and Blake [20], but lower than the 98 ml.min
-
1
.(1.73m
2
)
-1
 in the Granerus and Aurell study [18]. The data in the subgroup 40 years and older 
has to be interpreted with caution, however, as it comprised only 44 individuals and covered a 
relatively limited age range compared to the other studies. 
 
The results of Granerus and Aurell [18] and Hamilton et al [19] are not directly comparable due 
to small differences in methodology. On the other hand, the current study is based on the 
protocol described in the BNMS guidelines [2], as was the study by Grewal and Blake [20], 
making it more appropriate for comparison.  
 
It is accepted that GFR declines with age, although a cut-off age for the start of the decline is 
difficult to establish as recently shown by Peters et al [16]. No clear age cut-off could be 
identified in the current study, however a threshold of 40 years of age was chosen in 
accordance with the cut-off age used in a previous study [20]. Due to a relatively small study 
sample, individuals were not divided into groups based on gender, however, mean BM-GFRCorr 
was 107.0 ± 14.9 (1SD) ml.min
-1
.(1.73m
2
)
-1
 in men vs. 100.7 ± 17.9 (1SD) ml.min
-1
.(1.73m
2
)
-1
 in 
women. The difference was statistically significant (p = 0.04), however, the difference might be 
explained by the fact that the male cohort was significantly younger than the female cohort 
(mean age 30.5 versus 36.4 years, p = 0.002). These mean values for GFR in men and women 
are higher than those described in the multi-centre UK study [16], but this can be explained by 
two factors: firstly, the majority of GFR measurements (1783 of 1878) in the multi-centre study 
were performed using 
51
Cr-EDTA and secondly, the mean age of subjects in all the individual 
centres was higher than the mean age of subjects in the current study. Due to the relatively 
small study population, individuals in the current study could not be sub-divided into groups 
based on other factors such as obesity as was done in the multi-centre study [16]. 
 
In another study by the same authors the coefficient of variation (CV) of ECV-BSA in normal 
subjects was found to be useful in assessing departmental performance as it reflects the 
‘technical robustness’ with which the department performs the GFR measurements [34]. The 
authors suggest a range of 10-20% as acceptable. The CV for ECV-BSA in this study (using the 
adult Brochner-Mortensen correction equation [8]) was 15%. 
 
The BNMS guidelines state that, where practical, a minimum of 10 000 counts should be 
obtained for each sample in order to reduce statistical errors [2]. In this study, 70 of the 126 
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GFR studies contained samples with fewer than 10 000 counts. The systematic error (1SD) in 
GFR and VD values due to counting error was found to be low (0.19% and 0.64% respectively). 
As expected, the random error (1SD) was higher (GFR 2.97% and VD 10.19%). Another 
deviation from the BNMS guidelines was that no correction was made for the decay of Tc-99m. 
The resultant systematic error (1SD) was negligible in all cases (GFR -0.12% and VD -0.22%) 
therefore it was ignored in further calculations. The random error (1SD) was larger (GFR 1.81% 
and VD 2.37%). By assuming that the error measured in the 26 cases represented the error 
introduced through not correcting for decay in all 126 studies, the combined random error of 
noise and lack of decay correction could be calculated. This resulted in 3.5% for GFR and 
10.5% for VD (1SD). 
 
The components of the relatively high combined random error in VD were assessed further. In 
the correlation of uncorrected VD against BSA, a 1SD error expressed as a percentage of the 
mean VD is 20.3% (equation 9). Part of this variation will be genuine variability of VD with BSA, 
y%, and part due to experimental error. The two components add in quadrature: 
 
20.3
2
 = y
2
 + 10.5
2
            (14) 
 
The real standard deviation variation of uncorrected VD with BSA, y, is therefore 17.4%.  
Similarly, for corrected VD, a 1SD error expressed as a percentage of the mean is 17.2% 
(equation 10) and the real standard deviation variation with BSA is 13.6%. These results show 
that, because the error in VD is relatively large, the contribution of low counts and lack of decay 
correction to this variability is small.  
 
It is worth mentioning that a cohort of 126 studies is relatively small, therefore further larger 
studies are recommended to better define reference data for GFR using 
99m
Tc-DTPA. Secondly, 
the age of all individuals fell between 18 and 59 years, with few over the age of 50, as these 
were the subjects being considered as kidney donors. Ideally, a study of this nature should 
include subjects over a wider range of ages, including individuals over the age of 60 years as 
these are often the patients referred for GFR studies. Moreover, although the hospital’s 
screening process for kidney donors is intensive, it may not have been rigorous enough to 
exclude all subjects with mild renal pathology.  
 
Having defined the variation of volume of distribution with body surface area and its expected 
variation, this data may be used for quality control.  Studies in which the value of VD lies outside 
the expected limits for the subject’s BSA may be deemed fail the quality control (QC) test.  
Considering the corrected VD data shown in Figure 2, two of the studies lie well away from the 
2SD limits and therefore may be considered to fail the QC requirements.  Using 2SD limits, 5% 
of the studies will lie outside the limits due to natural statistical variation, therefore in practical 
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use wider limits might be used e.g. 2.5 or 3 SD.  Several different methods of calculating 
volume of distribution exist and it is therefore important that in using this parameter in quality 
control values must be compared to the corresponding normal range for that particular 
estimation of the volume. A similar test may be applied to the measured T½. This is compared to 
the expected limits of T½ for the subject’s normalized GFR and if it lies outside these, then the 
study is deemed to fail the QC test (figure 4).  One limitation of the current data in this respect is 
that it only contains data from control subjects.  To obtain a better fit for low GFR further data is 
required. 
 
Conclusion 
This study has defined reference data for GFR, VD and T½ from GFR studies using 
99m
Tc-DTPA 
in a healthy South African adult population. VD and T½ values can provide useful quality control 
checks for GFR studies performed using the slope-intercept method as described in the BNMS 
guidelines [2]. Reference data for GFR will enhance the interpretation of adult 
99m
Tc-DTPA GFR 
measurements. The small difference in normal values for GFR in comparison to previous 
studies using 
51
Cr-EDTA is in agreement with previous publications. 
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Legend to figures 
Figure 1 
Scatter graph of the uncorrected values of volume of distribution [VD (uncorrected)] in litres plotted as 
a function of BSA. The central line represents equation 9, the upper and lower lines (dashes) 
represent ± 2SD (± 40.6%). The faint dotted lines represent the upper and lower limits of the 
reference range described in BNMS guidelines (8*BSA ± 25%) (2SD) [2]. There is overlap of the 
two lines representing - 2SD.  
Figure 2 
Scatter graph of corrected values of volume of distribution [VD (corrected)] in litres plotted as a 
function of BSA. The central line represents equation 10, the upper and lower lines (dashes) are 
± 2SD (± 34.4%). The faint dotted lines represent the upper and lower limits of the reference 
range determined by University Hospital Southampton (6.61*BSA
1.218
) ± 32% (2SD) [13]. 
Figure 3 
Scatter graph of T½ (min) plotted as a function of age (years). The central line represents the 
mean in individuals under the age of 40 years and the equation-predicted-mean in individuals 
40 years and older (equation 11). The upper and lower lines are ± 2SD (± 36.2% in individuals < 
40 years and ± 36.7% in individuals ≥ 40 years). 
Figure 4 
Scatter graph of T½ (min) plotted as a function of (1/BM-GFRCorr) [min.(1.73m
2
).ml
-1
)]. The 
central line represents T½ fitted to equation 12 and the upper and lower lines represent ± 2SD (± 
35.1%). 
Figure 5 
Scatter graph of BM-GFRCorr [ml.min
-1
.(1.73m
2
)
-
1] as a function of age (18-59 years) in 126 
potential kidney donors. GFR values were corrected for BSA and using the mean Brochner-
Mortensen equation [2,8]. The central line represents the mean GFR in individuals under the 
age of 40 years and the mean fitted to equation 13 in individuals 40 years and older. The upper 
and lower lines represent ± 2SD (± 27.5% in individuals under the age of 40 years and 36.7% in 
individuals older than 40). 
 
 
 
